Tag results:
Publication
Hematopoiesis News
Cdc73 Protects Notch-Induced T-cell Leukemia Cells from DNA Damage and Mitochondrial Stress
[Blood] To find alternative ways to target Notch signals, researchers investigated Cell division cycle 73 (Cdc73), which is a Notch cofactor and key component of the RNA polymerase-associated transcriptional machinery, an emerging target in T cell acute lymphoblastic leukemia.
Hematopoiesis News
Hematopoietic-Specific Heterozygous Loss of Dnmt3a Exacerbates Colitis-Associated Colon Cancer
[Journal Of Experimental Medicine] Scientists hypothesized that bone marrow–derived cells with heterozygous loss-of-function mutations of DNMT3A, the most common genetic alteration in clonal hematopoiesis, contributed to the pathogenesis of colon cancer.
Hematopoiesis News
Autophagy Preserves Hematopoietic Stem Cells by Restraining MTORC1-Mediated Cellular Anabolism
[Autophagy] Researchers addressed why autophagy depletion led to a drastic loss of the stem cell compartment. Using inducible deletion of autophagy specifically in adult HSCs and in mice chimeric for autophagy-deficient and normal HSCs, they demonstrated that the stem cell loss is cell-intrinsic.
Hematopoiesis News
miR-126 Identifies a Quiescent and Chemo-Resistant Human B-ALL Cell Subset That Correlates with Minimal Residual Disease
[Leukemia] Investigators exploited patient-derived xenograft models with B cell acute lymphoblastic leukemia (B-ALL) cells transduced with a miR-126 reporter allowing the prospective isolation of miR-126(high) cells for their functional and transcriptional characterization.
Hematopoiesis News
Feasibility of Peripheral Blood Stem Cell Collection from Sickle Cell Trait Donors with an Intensified G-CSF Regimen
[European Journal Of Haematology] In this retrospective analysis, researchers compared the safety and efficacy of peripheral stem cell mobilization with a G-CSF intensified mobilization regimen in sickle cell trait donors with a conventional G-CSF mobilization regimen in healthy donors.
Hematopoiesis News
Phase I Study Evaluating the FC-Optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease
[Journal Of Hematology & Oncology] This first-in-human, open-label, single-arm, multicenter trial included AML patients in complete remission with persisting or increasing measurable residual disease and evaluated safety/tolerability, pharmacokinetics and preliminary efficacy of FLYSYN at different dose levels administered intravenously.